

Supplemental Digital Content 1. Disease-modifying therapy attributes and levels

Attributes	Levels	Description
Disability progression	2	<ul style="list-style-type: none"> ▪ No progression: EDSS score stable or increase <1.0 (if prior EDSS is 0-5.5) or stable (if prior EDSS >5.5) plus motor worsening <20% in T25FW and/or 9-HPT in 2 years ▪ Progression: EDSS score increase ≥1.0 (if prior EDSS is 0-5.5) or ≥0.5 (if prior EDSS >5.5) plus motor worsening ≥20% in T25FW and/or 9-HPT in 2 years
Cognition	2	<ul style="list-style-type: none"> ▪ No cognitive impairment (PASAT score < 35) ▪ Cognitive impairment (PASAT score ≥ 35)
Side effects and safety monitoring	2	<ul style="list-style-type: none"> ▪ Frequent, but mild-moderate side effects plus monitoring every 3-6 months ▪ Infrequent, but severe side effects (e.g.: PML, hepatotoxicity, secondary autoimmune disorders) plus monitoring 1-2 times a month
Route of administration	2	<ul style="list-style-type: none"> ▪ Self-administered ▪ Hospital administration
Frequency of administration	3	<ul style="list-style-type: none"> ▪ At least twice a month ▪ Monthly ▪ Every 6 months

Abbreviations: 9-HPT, Nine-Hole Peg Test; EDSS, Expanded Disability Status Scale; PML, Progressive multifocal

leukoencephalopathy; PASAT, Paced Auditory Serial Addition Test; T25FW, Timed-25 Foot Walk Test.